About the Authors
- Lars Steinstraesser
-
Contributed equally to this work with: Lars Steinstraesser, Tobias Hirsch
* E-mail: lars.steinstraesser@ruhr-uni-bochum.de
Affiliation Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Tobias Hirsch
-
Contributed equally to this work with: Lars Steinstraesser, Tobias Hirsch
Affiliation Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Matthias Schulte
-
Affiliation Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Maximilian Kueckelhaus
-
Affiliation Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Frank Jacobsen
-
Affiliation Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Evgenija A. Mersch
-
Affiliation Department of Plastic Surgery, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Ingo Stricker
-
Affiliation Institut for Pathology, BG University Hospital Bergmannsheil, Ruhr University Bochum, Bochum, Germany
- Nicole Afacan
-
Affiliation Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada
- Havard Jenssen
-
Affiliation Department of Science, Systems, and Models, Roskilde University, Roskilde, Denmark
- Robert E. W. Hancock
-
Affiliation Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada
- Jason Kindrachuk
-
Affiliation Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada
Competing Interests
Peptide IDR-1018 has been filed for patent protection by Hancock and assigned to his employer, the University of British Columbia. It has been licenced to Elanco for development as a therapy in animal health applications, and has been approved by Cystic Fibrosis Canada for pre-clinical development as an anti-inflammatory treatment for CF lung disease. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: LS JK TH FJ REWH. Performed the experiments: TH MS MK FJ EM. Analyzed the data: MS TH MK FJ. Contributed reagents/materials/analysis tools: HJ NA IS. Wrote the paper: TH LS MS FJ JK REWH.